Medical Oncology Unit, Dr. Peset University Hospital, Valencia, Spain.
Clin Transl Oncol. 2012 Jul;14(7):491-8. doi: 10.1007/s12094-012-0830-2.
Neutropenia induced by chemotherapy (CT) is an infection risk factor associated to greater morbidity/mortality and dose-limiting toxicity that on many occasions requires a reduction of the dose of cytostatics or a delay in the administration of treatment. This may have a negative effect on the patient's quality of life and even diminish the efficacy of the treatment, especially when the intention is to cure or prolong survival. Management of treatment or prophylaxis of grade 3-4 neutropenia and febrile neutropenia with myeloid growth factors (CSF) varies very much in clinical practice, both in the time of starting treatment and the types of patients it is given to. The need to generalise and facilitate practice based on clinical evidence has led the Spanish Society of Medical Oncology (SEOM) to prepare clinical practice guidelines on the use of myeloid growth factors.
化疗引起的中性粒细胞减少症（CT）是一种感染风险因素，与更高的发病率/死亡率和剂量限制毒性相关，在许多情况下需要减少细胞毒药物的剂量或延迟治疗的给予。这可能会对患者的生活质量产生负面影响，甚至降低治疗的疗效，尤其是当意图是治愈或延长生存时间时。临床实践中，对于 3-4 级中性粒细胞减少症和发热性中性粒细胞减少症的治疗或预防管理，使用骨髓生长因子（CSF）的方法差异很大，包括治疗开始的时间和给予患者的类型。为了概括和促进基于临床证据的实践，西班牙肿瘤内科学会（SEOM）制定了关于骨髓生长因子使用的临床实践指南。
